tbuckley/cabot-search huggingface dataset:
EP.11A.08 Real-World Comparative Effectiveness in Advanced NSCLC and High PD-L1 with 1L Immune Checkpoint Inhibitors ± Chemotherapy
Authors: M.L. Hsu, Q. Xia, S. Aggarwal, E. Nkhoma, D. R, T. Hager, R. Quek, J. Feliciano
Journal: Journal of Thoracic Oncology (2024)
EP.06G.03 Newly WHO Reporting System for Lung Cytopathology: Reproducibility Test of the Diagnosis
Authors: Y. Minami, A. Takenaka, K. Hiroshima, A. Yoshizawa, R. Haba, K. Kawahara, Y. Shibuki, S. Miyake, H. Kakinuma, Y. Satoh
Journal: Journal of Thoracic Oncology (2024)
EP.08F.19 Dosimetric Benefits in Adaptive Intensity Modulated Radiotherapy with Sib for Lung Cancer: An Indian Regional Cancer Centers' Early Experience
Authors: S.S. Das, A. Ray, D.K. Ray, B. Pramanik, M. Mahawar, S. Kundu, K. Mazumder, S. Mandal, S. Mandal, S. Bera
Journal: Journal of Thoracic Oncology (2024)
EP.04C.03 A Forgotten Group for Lung Cancer Screening: Lung Cancer in Patients with Aortic Aneurysms
Authors: R. Painter, A. Chau, T. Liang, A. Painter, M. Hegazi, C. Lee, N.-K. Kabutey, A. Mahtabifard, H. Keshava
Journal: Journal of Thoracic Oncology (2024)
EP.07E.03 TP53 Co-Mutations Increase Risk of Recurrence in EGFR-Mutated Stage I Lung Adenocarcinoma
Authors: F.T. Gallina, D. Marinelli, R. Tajè, E. Melis, P. Visca, S. Buglioni, F. Cappuzzo, S. Najmeh, J. Cools-Lartigue, L. Ferri, S. Camilleri Broet, P.O. Fiset, J. Spicer
Journal: Journal of Thoracic Oncology (2024)
EP.07D.05 Molecular Testing Care Gap Analysis of EGFR Mutation for Early-Stage NSCLC Patients in Community Practices
Authors: J. Dow, N. Zimmerman, S. Monzon, W. Zhao, A. Barrett, V. Erese, C. Gurbatri, E. Cohen, C. ScottoDiVetta, I. Huerga, H. Nimeiri, D.H. Owen, J.D. Patel
Journal: Journal of Thoracic Oncology (2024)
EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas
Authors: P.J. Voon, J.-L. Tan, A.I. Spira, B. Keam, S.-H. Lee, B. Xia, E. Artis, J. Dobbs, C. Baudelet, M. Baig, J.M. Bauml, M.A. Sendur, B.C. Cho
Journal: Journal of Thoracic Oncology (2024)
EP.03F.05 A Dose-Effect Relationship of a Novel Bronchoscopy Guided Endobronchial Radiofrequency Ablation for Peripheral Lung Tumors
Authors: W. Ji, J. Seo, C. Lee, M.-K. Chon, W. Kim, C.G. Kang, J.-H. Kim
Journal: Journal of Thoracic Oncology (2024)
EP.12A.19 Race May Affect Survival in 1L Patients with Metastatic Non-Small Cell Lung Cancer (mNSLC) Onegfr-Targeted Therapy
Authors: A. Barsouk, O. Elghawy, G. Yang, A. Heidlauf, C. Yu, L. Wang, K. Goel, L. Rushkin, A. Huang, L. Sun, A. Singh, R.B. Cohen, C. Aggarwal, M. Marmarelis, C. Langer
Journal: Journal of Thoracic Oncology (2024)
EP.06D.01 Prognostic Evaluation by Using ctDNA in Patients with EGFR Mutated Resectable Lung Cancer
Authors: Y. Murase, H. Koba, T. Ueda, S. Arai, N. Terada, Y. Tambo, S. Nanjo, S. Yano
Journal: Journal of Thoracic Oncology (2024)
EP.06C.06 Outcome and Clinical Profile of Common and Uncommon EGFR Mutations in NSCLC: Retrospective Analysis from an Argentinean Cancer Center
Authors: F. Guerra, M. Bonet, A. Matteo, M. Altamirano, C. Gagliolo, M. Krasnapolski, M. Castro
Journal: Journal of Thoracic Oncology (2024)
EP.07E.05 Prevalence of EGFR Mutations (EGFRm)in Patients with Early-Stage NSCLC - Results from EARLY-EGFR Thailand Study
Authors: T. Thamrongjirapat, C. Akewanlop, K. Khiewngam, A. Tantraworasin, P. Danchaivijitr, T. Reungwetwattana, S. Saeteng
Journal: Journal of Thoracic Oncology (2024)
EP.06B.01 The Actual Status of Biomarker Testing and Prognosis in Postoperative Recurrent NSCLC: Subgroup Analyses of WJOG15421L (REVEAL)
Authors: T. Matsubara, T. Sakamoto, T. Takahama, T. Yokoyama, I. Yoshino, H. Akamatsu, M. Yamaguchi, S. Miura, T. Tokito, M. Tachihara, Y. Sato, T. Takenaka, K. Sugio, M. Mori, T. Takeuchi, M. Hiraoka, H. Kenmotsu, J. Fujimoto, M. Shimokawa, N. Yamamoto, K. Nakagawa
Journal: Journal of Thoracic Oncology (2024)
EP.06E.05 Is Diffusion-Weighted Imaging Able to Indicate Pathological Response in NSCLC after Neo-Adjuvant Immuno-Chemotherapy?
Authors: D. Kifjak, H. Prosch, M. Hochmair, G. Langs, S. Pochepnia, A. Korajac, B.H. Heidinger, R.-I. Milos, M. Hacker, L. Beer
Journal: Journal of Thoracic Oncology (2024)
EP.05A.04 Risk Factors for the Development of Pulmonary Infection after Bronchoscopy in Patients with Lung Cancer - A Centre in Greece
Authors: V. PAPAVASILEIOU, T. RAPTAKIS, S. LAMPADAKIS, I. VOULGARELI, A. PAPAVASILEIOU, A. KARAKATSANI, S. LOUKIDES, K. SYRIGOS
Journal: Journal of Thoracic Oncology (2024)
EP.07F.05 The Neutrophil/Lymphocyte Ratio Predict Lymph Node Metastasis in Patients with Clinical Stage T2 Non-Small Cell Lung Cancer.
Authors: S. Mizuguchi, T. Higashiyama, S. Yamamoto, A. Ueno, K. Chung, R. Nakajima
Journal: Journal of Thoracic Oncology (2024)
EP.04A.01 Lung Cancer Nurse Consultant-Led Pulmonary Nodule Assessment and Surveillance Clinic: Multidisciplinary Team Evaluation
Authors: V.N. Brunelli, S. Karipidis, A.C. Jones, D. Jeffery, J. Bianco, H. Marshall, K.M. Fong, D.C. Currow
Journal: Journal of Thoracic Oncology (2024)
EP.06C.03 Clinicopathological Analysis of Each EGFR Status in Surgically Resected Lung Adenocarcinoma: A Real-World Study (CReGYT-01 EGFR)
Authors: H. HOSHINO, S. Katsumata, A. Hamada, N. Haratake, K. Nomura, K. Fujino, M. Yoshikawa, K. Suzawa, K. Shien, K. Suda, S. Ohara, S. Fukuda, I. Kinoshita, K. Hayasaka, H. Notsuda, S. Takamori, S. Muto, Y. Takanashi, K. Mizuno, A. Kawase, T. Hayakawa, K. Sekihara, M. Toda, S. Matsuo, K. Takegahara, M. Hashimoto, K. Nakahashi, M. Endo, H. Ozawa, R. Fujikawa, Y. Tomioka, K. Namba, T. Matsubara, J. Suzuki, H. Watanabe, K. Takada, T. Toyoda, S. Nakasone, H. Kawasaki, M. Shimokawa, Y. Kouki, S. Shiono, J. Soh, Y. Ohde
Journal: Journal of Thoracic Oncology (2024)
MA19.10 The Tracerx 421 Cohort Provides Insights to Key Pathological Features of Lung Squamous Cell Cancer
Authors: A. Cheung, D.A. Moore, T. Karasaki, C. Puttick, K. Grigoriadis, K.S.S. Enfield, A.M. Frankell, N. McGranahan, M. Jamal-Hanjani, C. Swanton
Journal: Journal of Thoracic Oncology (2024)
EP.06G.10 Comprehensive Analysis of the Clinicopathological Features, Targetable Profle, and Prognosis of Mucinous Adenocarcinoma of the Lung
Authors: D. Ueda, A. Kamigaichi, N. Tsubokawa, T. Mimae, Y. Miyata, N. Tatsumoto, M. Okada
Journal: Journal of Thoracic Oncology (2024)
EP.08F.10 Semi-Automated NSCLC Segmentation and RECIST Measurement: Bridging the Gap Between Speed and Radiologist-Level Accuracy
Authors: K. Zhang, S. Lee, A. Hiremath, J. Lee, P. Kim, S. Lee, M. Yadav, M.J.A. Chuchuca, T. Um, M. Nam, L.I-Y. Chung, H.S. Kim, J. Yu, T.A. Djunadi, L. Kim, Y. Oh, S. Yoon, Z. Shah, Y. Kim, I. Hong, G. Kang, J. Jang, A. Cho, S. Lee, C. Nam, T. Hong, Y.S. Velichko, V. Velcheti, A. Gupta, A. Madabhushi, Y.K. Chae, N. Braman
Journal: Journal of Thoracic Oncology (2024)
EP.03F.02 Exploration of Acquired Resistance Mechanisms to the 4th-Generation EGFR-TKI in EGFR-Mutated Lung Cancer - An in Vitro Study
Authors: S. Fukuda, K. Suda, A. Hamada, H. Oiki, S. Ohara, M. Ito, J. Soh, T. Mitsudomi, Y. Tsutani
Journal: Journal of Thoracic Oncology (2024)
EP.12B.01 Weight Gain and Metabolic Changes Associated with Alectinib Use in ALK-Positive Lung Cancer
Authors: J. Maturi, M. Guo, P. Ghanem, J. Murray, S. Scott, S. Houseknecht, J. Feliciano, C. Hann, D. Ettinger, P. Forde, J. Brahmer, B. Levy, K. Marrone, V. Lam
Journal: Journal of Thoracic Oncology (2024)
EP.11C.04 Retrospective Evaluation of Biomarkers (KRAS, TP53, STK11, KEAP1, POLE, PIK3CA, ARID1A) In Patients with NSCLC IV
Authors: J. Roeper, M. Falk, S. Schatz, L. Heukamp, F. Griesinger
Journal: Journal of Thoracic Oncology (2024)
EP.11A.06 Somatic Gene Changes Associated with Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Authors: A.G. Pachimatla, S. Kalvapudi, S. Bawek, Y. Vedire, P. Jain, S. Yendamuri, S. Patnaik
Journal: Journal of Thoracic Oncology (2024)
EP.07C.16 Real-World Outcomes of Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemoimmunotherapy
Authors: A. Hazim, A. Xiao, A. Singh, K. Chung, P.A. Reck dos Santos, J. D'Cunha, M. Shanshal, A. Dimou, K. Parikh, Y. Lou, R. Manochakian, K. Leventakos, J. Molina, A. Mansfield, V. Ernani
Journal: Journal of Thoracic Oncology (2024)
EP.13D.03 Prognostic Factors of First-Line Immune Checkpoint Inhibitors in Combination with Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Authors: Y.-T. Liao, R.-L. Sun, H.-C.H. Huang, C.-I. Shen, Y.-H. Tseng, Y.-H. Luo, Y.-M. Chen, C.-L. Chiang
Journal: Journal of Thoracic Oncology (2024)
EP.06B.14 Differential Expression in Potential Therapeutic Target Protein by Treatment in Small Cell Lung Cancer with and without Transformation
Authors: S. Murata, H. Horinouchi, Y. Yatabe, J. Kashima, K. Masuda, Y. Shinno, Y. Okuma, T. Yoshida, Y. Goto, N. Yamamoto, S. Watanabe, Y. Matsumoto, K. Okuma, Y. Ohe
Journal: Journal of Thoracic Oncology (2024)
EP.08F.06 Concurrent Chemoradiotherapy Followed by Durvalumab for Elderly Patients
Authors: A. Yatani, N. Katsurada, T. Ishihara, N. Miwa, M. Katsurada, Y. Hatakeyama, Y. Kawa, S. Hori, S. Yoshimura, M. Tachihara
Journal: Journal of Thoracic Oncology (2024)
EP.12B.15 ALK-Fusion Positive NSCLCs: Diversity in Mutations and Co-Mutations with Therapeutic Perspective and Clinical Outcomes
Authors: A. Joshi, K. Joshi, U. Maheshwari, K. Jobanputra, D. Morzaria, V. Maniar, P. Kalaskar, R. Wategaonkar, R. Dave, S. Jagiasi, S. Sheth, T. Sethjiwala, C. Bose, P. Devde, P. Khandare
Journal: Journal of Thoracic Oncology (2024)
EP.12A.20 EGFR Inhibitors Combined with Intrathoracic Perfusion Manages Malignant Pleural Effusion in EGFR-Mutated Metastatic Lung Adenocarcinoma
Authors: W. Huang, S. Liao, X. Lei, Z. Chen, K. Xu, Y.-F. Wang, Q. Zhou, J. Liu
Journal: Journal of Thoracic Oncology (2024)
P1.13A.13 ALISertib in Patients with Extensive-Stage Small-Cell Lung Cancer: The Phase 2 ALISCA-Lung1 Study
Authors: T. Owonikoko, T.F. Burns, A.A. Chiappori, B. Drapkin, R.D. Gentzler, J. Goldschmidt, D. Hakimian, R. Jotte, S.V. Liu, A.A. Onitilo, N.A. Pennell, B. Potugari, J. Rios, J. Sands, A. Spira, B. Wang, D.M. Waterhouse, B. Lowenthal, J. Bebchuk, L.D. Eli, E.K. Wong, A. Dowlati
Journal: Journal of Thoracic Oncology (2024)
EP.13A.03 A Phase II Study of Vobramitamab Duocarmazine in Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
Authors: B. Gupta, J.P. Zaemes, V. Yeung, J. Reuss, V. Aggarwal, J. Thompson, N. Swanson, D. de Miguel Perez, J. Ahn, K. Chen, I. Veytsman, M. Gutierrez, C.D. Rolfo, S.V. Liu, C. Kim
Journal: Journal of Thoracic Oncology (2024)
EP.06F.06 Concurrent DNA and RNA NGS Testing to Characterize Rare Fusions in Advanced NSCLC Patients
Authors: J.L. Feliciano, L. Gai, Z. Rivers, A.J. Hockenberry, H. Nimeiri, K.A. Beauchamp, R. Ben-Shachar, J. Guinney, J. Patel
Journal: Journal of Thoracic Oncology (2024)
EP.09B.04 Neoadjuvant Chemo-Immunotherapy Followed by Radical Surgery for Synchronous Oligometastatic Non-Small Cell Lung Cancer
Authors: F.T. Gallina, F. Fusco, F.L. Cecere, R. Tajè, D. Forcella, L. Landi, G. Minuti, S. Buglioni, P. Visca, E. Melis, F. Facciolo, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2024)
EP.12A.32 Discontinuation of EGFR-TKI in NSCLC During COVID-19 Infection: Assessing Unvaccination, Low BMI, and Comorbidities
Authors: P. Huang, L.-M. Liao, J.-L. Zhao, C. Luo, Y.-L. Yi, Y. Chen, L. Huang
Journal: Journal of Thoracic Oncology (2024)
EP.08D.04 Association of Lymph Node Metastatic Patterns and Neoadjuvant Immunochemotherapy Effectiveness in Resectable Non-Small Cell Lung Cancer
Authors: Y. Zhou, Z. Lin, Y. Zheng, Y. Lin, Z. Zhao, D. Liu, W. Zhai, B. Rao, S. Feng, H. Long
Journal: Journal of Thoracic Oncology (2024)
EP.08F.13 Machine Learning Analysis of Cardiac Sub-Structure Dose and Overall Survival of NSCLC Pts Treated with Concurrent Definitive Chemoradiotherapy
Authors: T.J. Dilling, A. Allen, O. Edrich, D. Dudas, D.H. Lee, D. Money, G. Eichelberger, A. Kumar, J.M. Bryant, R.J. Cruz-Chamorro, E. Keit, V. Feygelman, E. Scott, S.A. Rosenberg, I. El Naqa
Journal: Journal of Thoracic Oncology (2024)
EP.08D.07 Pathological Response to Neoadjuvant Tislelizumab Plus Chemotherapy in Potentially Resectable Stage IIIB NSCLC
Authors: T. Wang, P.-L. Wang, Y.-X. Song, H. Chen, L. Li, Y. Wang, L.-R. Ding, X.-J. Huang, B. Zheng, J.-R. Zhang, J.-W. Liu, D.-X. Zhu, L. Tian, L.-L. Jiang, P. Zhou, M.-G. Su, D. Pu, R. Jiang, K.-L. Huang, Y.-S. Wang#, C. Chen#, Q.-H. Zhou#
Journal: Journal of Thoracic Oncology (2024)
EP.08E.06 The Peripheral Bronchial Occlusion or Stenosis after Dumon Y-stenting is Prognostic Factor in Patients with Advanced Lung Cancer
Authors: T. Higashiyama, S. Mizuguchi, R. Nakajima, K. Chung, A. Ueno, S. Yamamoto
Journal: Journal of Thoracic Oncology (2024)
EP.04E.06 The Prediction of Spread Through Air Spaces with Preoperative 18F-FDG PET/CT in Clinical Stage I Lung Cancer
Authors: G. Kocaman, C. Soydal, S. Dursun, Y. Kahya, S. Dizbay Sak, A. Kayı Cangır
Journal: Journal of Thoracic Oncology (2024)
EP.04C.09 Liquid Biopsy Assay to Detect Low Levels of ctDNA in Early-Stage Lung Cancer Samples
Authors: M. Smith, M. Salmans, M. Wang, A. Carson, B.-I. Lee, K. Cabrera, K. Fathe, M. Francis, B. Leatham
Journal: Journal of Thoracic Oncology (2024)
EP.07H.01 Analysis of Variables Predicting pCR and irAEs in Resectable NSCLC Receiving Neoadjuvant Immunotherapy with Chemotherapy (Pre-PLaN)
Authors: S. Verma, D. Breadner, R. Nayak, M. Black, R. Malthaner, J. Raphael, T. Appleton, M. Silverman, M. Sanatani, R. Inculet, D. Fortin, P. Blanchette, S. Kuruvilla, M. Qiabi, J. Younus, D. Logan, B. Hedley, I. Chin-Yee, J. Burton, M. Vincent
Journal: Journal of Thoracic Oncology (2024)
EP.07C.05 Efficacy and Safety of Aumolertinib in Stage IB-IIIA NSCLC after R0 Resection and the Correlation Between Efficacy and Postoperative MRD Status
Authors: S. Yang, X. Zhang, Z. Chen, Y. Xiong, C. Zeng, M. Pan, Q. Chen
Journal: Journal of Thoracic Oncology (2024)
EP.14A.09 Influence of Post-Pleurectomy/Decortication Peritoneal Dissemination Recurrence of Pleural Mesothelioma on Long-Term Survival
Authors: A. Nakamura, M. Hashimoto, A. Fukuda, K. Takegahara, A. Kuroda, S. Matsumoto, N. Kondo, S. Funaki, S. Hasegawa
Journal: Journal of Thoracic Oncology (2024)
EP.16F.03 Lung Cancer Patients' Preferred Methods of Involvement with their Treatment Teams: Insights from a Global Patient Experience Survey
Authors: K. Clayton, M. Daniels, J. Fox, B. Gaspar, M. Hennink, J. Mayans, A. McNamara, L. Pretorius, M. Rigney, M. Dohr
Journal: Journal of Thoracic Oncology (2024)
EP.11A.18 LUMINATE 101-Maccabi: Real-World Study of Treatment Patterns and Clinical Outcomes in Patients with Mnsclc in an Israeli HMO
Authors: J. Bar, S.S. Moser, A. Zer Kuch, N. Passwell, M. Hoshen, H. Alhasani, A. Virani, N. Daaboul, Q. Xu, S. Gazit
Journal: Journal of Thoracic Oncology (2024)
P4.17F.03 Utilizing AI for Automated Data Entry and Analysis to Pre-Screen Lung Cancer Clinical Trial Candidates
Authors: M. Aldea, P. Rolland, L. Zullo, S. Simon, A. Djarallah, A. Poplu, M. Wartelle, L. Chutto, B. Vignal, J.-C. Louis, F. Lion, S. Platano, D. Planchard, A. Gazzah, C. Baldini, C. Robert, F. Andre, F. Barlesi, S. Michiels, F. Le Ouay, B. Besse
Journal: Journal of Thoracic Oncology (2024)
EP.09B.01 Closing the Gap: Moving Toward Equitable Care in Surgical Management of Stage IV Lung Disease
Authors: S.A. Ries, Y. Qing, R. Sun, J. Mitchell, M. Eisenberg, K. Mitchell, R. Mehran, D. Rice, J. Roth, S. Swisher, A. Vaporciyan, S. Swisher, W. Hofstetter, R. Rajaram, M.A. Antonoff
Journal: Journal of Thoracic Oncology (2024)
EP.12A.29 Characteristics of Osimertinib Non-Responders vs Responders in EGFR Mutated Lung Cancer
Authors: A. Reyes, S. Sampath, R. Muddasani, M. Afkhami, A. Amini, V. Villaflor, R. Salgia, A. Rock, X. Li, E. Massarelli
Journal: Journal of Thoracic Oncology (2024)
EP.17A.08 Development of the First Lung Cancer Clinical Pathway in Chinese Counties
Authors: Q. Zhou, D. Zhao, F. Lin, J.-H. Wang, J. Yan, P. Lu, R.-P. Li, S.-G. Kuang, T. Wu, X. Tan, X.-P. Deng, Y. Han, Y.-L. Wu
Journal: Journal of Thoracic Oncology (2024)
EP.11A.03 Anti-PD-1 Therapy Plus Denosumab in Advanced Non-Small Cell Lung Cancer with Bone Metastases: A Single-Centre, Retrospective Study in China
Authors: J. Zhou, J. Qu, N. Liu, Q. Shen, J. Zheng, Y. Li, J. Zhou
Journal: Journal of Thoracic Oncology (2024)
EP.14B.05 What Do We Know About Thymic Epithelial Tumors? Demographic and Survival Analysis from a Single Academic Center in Argentina
Authors: D.E. Mansilla, M.F. Guerra, J.L. Lopez, L. Arias, E. Rojas Bilbao, M. Castro, A. Gilardoni
Journal: Journal of Thoracic Oncology (2024)
EP.13E.02 Multi-Omics Analysis of Patients with Extended-Disease Small Cell Lung Cancer Who Received Chemoimmunotherapy: APOLLO-Bio Study
Authors: H. Akamatsu, D. Fujimoto, M. Nakatochi, M. Tamiya, T. Kijima, Y. Sato, H. Matsumoto, A. Hata, S. Hara, Y. Taniguchi, T. Yokoyama, J. Uchida, S. Miura, N. Furuya, J. Sugisaka, E. Miyauchi, S. Sakata, H. Tanaka, N. Yamamoto, Y. Koh
Journal: Journal of Thoracic Oncology (2024)
EP.12A.41 First-Line Treatment of EGFR-Mutant NSCLC: TKI Alone or Combinations - What I Use Today and Why in the Latin America vs the World
Authors: G.V. Bon, E.A. de Laia, C.M. Peixoto, G.B. Trotte, C.V.Y. de Oliveira, G.P. Silvestre, P.H.A. da Costa, R.T. Dias, L.F.d.L. Martins, C.D.C.e. Silva, V.M.L. dos Santos
Journal: Journal of Thoracic Oncology (2024)
EP.07A.15 Prognosis after Surgical Treatment of Lung Cancer with Multifocal Ground-Glass Nodules: The Effect of Nodule Characteristics
Authors: J.H. Park, T. Yun, B. Na, K.J. Na, S. Park, C.H. Kang, Y.T. Kim, I.K. Park
Journal: Journal of Thoracic Oncology (2024)
EP.08D.13 Macrophage Polarization States Predicting the Efficacy of Neoadjuvantchemoimmunotherapyin Resectable or Potentially Resectable NSCLC
Authors: Z. Xu, K. Shao, Y. Li, J. Ying, T. Xie, P. Xing, J. Li
Journal: Journal of Thoracic Oncology (2024)
EP.06F.03 Analysis of Copy Number Variations of MET, EGFR and ERBB2 Genes in a Lung Cancer Patient Series: Comparison of FISH with NGS
Authors: S. Buglioni, C. Ercolani, A. Di Benedetto, I. Terrenato, A. Palange, G. Americi, P. Visca, E. Pescarmona, G. Minuti, L. Landi, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2024)
EP.07D.09 A Global Study to Evaluate Access and Dynamics of Multidisciplinary Teams Care and Biomarker Testing in Early-Stage NSCLC
Authors: T. Leal, H. Bahig, S. Schmid, T.D. Alves Pinto, D. Simmons, M. Shanahan, L. Qiao, M.K. McCann, R. Rawlinson, M. Strebl-Bantillo, T.R. Rasmussen
Journal: Journal of Thoracic Oncology (2024)
EP.12B.07 Identification of Candidate Therapeutic Targets Using Single Cell RNA Sequencing in ALK-Positive Lung Cancers
Authors: M.A. Muskavitch, R.B. Hall, J. Lowy, E. Gefroh, E.S. Venanzi, J. Noonan, K. Li
Journal: Journal of Thoracic Oncology (2024)
EP.12A.01 Preclinical Characterization of a Potent, Selective, Brain-Penetrant Inhibitor of Osimertinib-Resistant EGFR Variants
Authors: K. Amberg-Johnson, J. Xu, H. Izadi, R. Kannan, S. Ellery, S. Kurhade, A. Verras, J. Guo, B. Jean, M. Svensson, P. Hsiao, E. Evangelista, Z. Liu, J. Bell, A. Futran, K. Akinsanya, K.K. Jensen
Journal: Journal of Thoracic Oncology (2024)
EP.12H.05 Phase II Study on Platinum-Pemetrexed and Lorlatinib Combination in ALK-Positive NSCLC Extracranially Progressing on Lorlatinib
Authors: E. Bertoli, E. Da Carlo, A. Del Conte, B. Stanzione, M. Montico, F. Mazzoni, A. Camerini, D. Cortinovis, A. Delmonte, G. Metro, G. Pasello, G. Pelizzari, M. Tiseo, T. Battistuzzi, A. Bearz
Journal: Journal of Thoracic Oncology (2024)
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments
Authors: Aung Naing, Danny Khalil, Oliver Rosen, D Ross Camidge, Tom Lillie, Rui-Ru Ji, Andrea Stacey, Matthew Thomas, Lee Rosen
Journal: Journal for ImmunoTherapy of Cancer (2024)

Background Tumor-selective oncolytic viral vectors are promising anticancer therapeutics; however, challenges with dosing and potency in advanced/metastatic cancers have limited efficacy and usage. NG-350A is a next-generation blood-stable adenoviral vector engineered to express an agonist anti-cluster of differentiation (CD)40 antibody without affecting tumor-selectivity and oncolytic potency. Methods Intravenous and intratumoral (IT) administration of NG-350A was assessed in a phase Ia/Ib study in patients with metastatic/advanced epithelial tumors ( NCT03852511 ). Dose-escalation was performed separately for intravenous (four dose levels available, each with infusions on Days 1, 3 and 5 of a 57-day treatment period) and IT (single injection on D1 only or injections on Days 1, 8, 15 and 22) administration. The primary objective was safety and tolerability; secondary objectives included determining a recommended dose, pharmacokinetics, and immunogenicity. Results In total, 25 heavily pretreated patients received NG-350A (16 with intravenous and 9 with IT administration). Intravenous and IT dosing were both well tolerated, with no evidence of transgene-related or off-target viral toxicity. Intravenous and IT dosing resulted in dose-dependent increases in systemic NG-350A C max . Despite both routes of administration inducing anti-virus antibodies, sustained persistence of NG-350A in blood samples was observed up to 7 weeks after the last dose, particularly with higher intravenous dose levels. Delivery of NG-350A to tumors was demonstrated in biopsy samples following both routes of administration; a dose-dependent pattern was seen with intravenous infusion, with four patients remaining positive for vector DNA in biopsies at Day 57. Transgene messenger RNA from replicating NG-350A was detected in 5/12 patients with intravenous treatment and 1/9 patients with IT injection, and sustained increases in inflammatory cytokines were observed following dosing, particularly with higher intravenous dose levels. Conclusions This phase 1a study provided initial proof-of-mechanism for NG-350A, with strong evidence of tumor delivery, viral replication and transgene expression—particularly after intravenous dosing. The lack of transgene-related or off-target viral toxicity was consistent with the highly selective delivery and replication of NG-350A, even after systemic delivery. The efficacy of intravenous-dosed NG-350A will now be evaluated in combination with pembrolizumab ( NCT05165433 ), as well as with chemoradiotherapy ( NCT06459869 ). Trial registration number NCT05165433 , NCT06459869 .
EP.06B.20 Prognostic Impact of Nectin-like Molecule-5 (CD155) Expression in Non-Small Cell Lung Cancer
Authors: N. Hernandez-Pedro, X. Popa-Navarro, A. Avilés-Salas, M. Orozco-Morales, E. Caballé-Pérez, C. Castillo-Ruiz, J. Lucio-Lozada, P. Barrios-Bernal, J.-M. Hernandez-Martinez, O. Arrieta
Journal: Journal of Thoracic Oncology (2024)
EP.03G.03 Tumor Treating Fields (TTFields) Induce Pro-Inflammatory Phenotype Skewing of Macrophages
Authors: T. Kan, Y. Barsheshet, B. Brant, T. Haj Khalil, T. Voloshin, A. Volodin, L. Koren, B. Koltun, A. Klein-Goldberg, E. Zemer-Tov, R. Paz, A. Haber, M. Giladi, U. Weinberg, Y. Palti
Journal: Journal of Thoracic Oncology (2024)
EP.04A.10 Creating Safe Connections: Usability Testing of an Intervention Co-designed to Increase Equitable Access to Lung Cancer Screening
Authors: A. Sayani, A. Hussain, H. Freedman, B. Amenu, V. Ramasamy, T. Jeji, A. Pratt, E. Nicholson, A. Lofters
Journal: Journal of Thoracic Oncology (2024)